Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Oncolytics Biotech Inc. (ONCY : NSDQ)
 
 • Company Description   
Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer.

Number of Employees: 28

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.92 Daily Weekly Monthly
20 Day Moving Average: 1,343,297 shares
Shares Outstanding: 94.28 (millions)
Market Capitalization: $86.73 (millions)
Beta: 1.07
52 Week High: $1.53
52 Week Low: $0.33
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 176.41% 161.44%
12 Week 83.94% 54.32%
Year To Date 0.67% -5.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
804 322 - 11 AVENUE SW
-
CALGARY,A0 T2R 0C5
CAN
ph: 403-670-7380
fax: 403-283-0858
jpatton@oncolytics.ca http://www.oncolyticsbiotech.com
 
 • General Corporate Information   
Officers
Wayne Pisano - Interim Chief Executive Officer and Chairman
Kirk Look - Chief Financial Officer
Allison Hagerman - Vice President
Christophe Degois - Vice President
Deborah M. Brown - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 682310875
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 94.28
Most Recent Split Date: 5.00 (0.11:1)
Beta: 1.07
Market Capitalization: $86.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.31 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 17.58
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 14.29%
vs. Previous Quarter: 14.29%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -313.77
12/31/24 - -223.42
ROA
06/30/25 - -
03/31/25 - -130.19
12/31/24 - -113.24
Current Ratio
06/30/25 - -
03/31/25 - 3.20
12/31/24 - 2.82
Quick Ratio
06/30/25 - -
03/31/25 - 3.20
12/31/24 - 2.82
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.05
12/31/24 - 0.05
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©